Browsing Category
Dry Powder Inhalers (DPI)
Complexities related to the amorphous content of lactose carriers
Abstract
Although the amount of amorphous content in lactose is low, its impact on the performance of a dry powder inhalation formulation might be high. Many formulators and regulatory agencies believe that the levels of amorphous content should be controlled once there is a relationship with the…
Read More...
Read More...
Supercritical antisolvent-fluidized bed for the preparation of dry powder inhaler for pulmonary…
The supercritical antisolvent-fluidized bed coating process (SAS-FB) shows great potential as a technique to manufacture dry powder inhaler (DPI) that incorporate nanodrugs onto micronized matrix particles, capitalizing on the merits of both nanoparticle and pulmonary delivery. In this study,…
Read More...
Read More...
Tailoring Dry Microparticles for Pulmonary Drug Delivery: Ultrasonic Spray Freeze-Drying with…
Abstract
Spray freeze-drying has emerged as a valid alternative to traditional spray drying to produce therapeutic dry microparticles. In particular, the spherical shape and high porosity of spray freeze-dried microparticles make them suitable for pulmonary drug delivery through dry powder…
Read More...
Read More...
Stability study of spray freeze-dried insulin dry powder formulations used for nose-to-brain…
Insulin is classified as a cold chain product due to being a peptide hormone with stability issues in the liquid preparation. Therefore, insulin was developed into the dry powder form to improve the stability and application for nose-to-brain delivery in Alzheimer’s disease treatment. Insulin was…
Read More...
Read More...
Microstructural insight into inhalation powder blends through correlative multi-scale X-ray computed…
Dry powder inhalers (DPI) are important for topical drug delivery to the lungs, but characterising the pre-aerosolised powder microstructure is a key initial step in understanding the post-aerosolised blend performance. In this work, we characterise the pre-aerosolised 3D microstructure of an…
Read More...
Read More...
Stepping into small shoes: Gaining user perspective on appropriate administration devices for…
A cross sectional pan-India study about use of administration devices for paediatric oral and inhalation medicines was conducted with a diverse pool of participants of various age groups. Via 634 respondents from more than 15 states in India, this study has identified the administration devices…
Read More...
Read More...
Evaluation of the Effects of Storage Conditions on Spray-Dried siRNA-LNPs Before and after…
In an ideal world, pharmaceutical drugs would have infinite shelf life, no susceptibility to degradation, chemical reactions or loss of efficacy. In reality, these processes occur, however, making it desirable to extend a drugs’ shelf life. Nucleic acid-based drugs are most commonly stored as…
Read More...
Read More...
Integrated continuous manufacturing of inhalable remdesivir nanoagglomerate dry powders: design,…
While inhalable nanoparticle-based dry powders have demonstrated promising potential as next-generation respiratory medicines, erratic particle redispersibility, and poor manufacturing reproducibility remain major hurdles hindering their translation from bench to bedside. We developed a one-step…
Read More...
Read More...
Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery
Abstract
Pulmonary delivery of mRNA via inhalation is a very attractive approach for RNA-based therapy for treatment of lung diseases. In this work, we have demonstrated successful development of an mRNA-lipid nanoparticle (LNP) dry powder product (DPP), wherein the LNPs were spray dried using…
Read More...
Read More...
Putting children first: Understanding caregivers’ and children’s perspectives on the usability of…
A multi-national online survey was developed to obtain feedback on users’ experiences of administration devices for oral and inhaled paediatric medicines. The questionnaire was divided into two identical parts: 1) for caregivers looking after children aged 0–18 years, and 2) for children aged 10 …
Read More...
Read More...